These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34422904)

  • 21. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
    Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
    Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
    [No Abstract]   [Full Text] [Related]  

  • 22. RELB: A novel prognostic marker for glioblastoma as identified by population-based analysis.
    Zeng F; Wang K; Huang R; Liu Y; Zhang Y; Hu H
    Oncol Lett; 2019 Jul; 18(1):386-394. PubMed ID: 31289510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry.
    Lu VM; Alvi MA; Bydon M; Quinones-Hinojosa A; Chaichana KL
    Clin Neurol Neurosurg; 2019 Jul; 182():32-36. PubMed ID: 31063969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular markers in low-grade gliomas: predictive or prognostic?
    Hartmann C; Hentschel B; Tatagiba M; Schramm J; Schnell O; Seidel C; Stein R; Reifenberger G; Pietsch T; von Deimling A; Loeffler M; Weller M;
    Clin Cancer Res; 2011 Jul; 17(13):4588-99. PubMed ID: 21558404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
    Branzoli F; Pontoizeau C; Tchara L; Di Stefano AL; Kamoun A; Deelchand DK; Valabrègue R; Lehéricy S; Sanson M; Ottolenghi C; Marjańska M
    Neuro Oncol; 2019 Jun; 21(6):765-774. PubMed ID: 30726924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Siglec10-An immunosuppressor and negative predictor of survival prognosis in gliomas.
    Wang H; Feng Y; Zhang Y; Wang T; Xu H; Zhi Y; Feng Y; Tian L; Yuan K
    Front Genet; 2022; 13():873655. PubMed ID: 36468012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas.
    Franceschi E; Tosoni A; Bartolini S; Minichillo S; Mura A; Asioli S; Bartolini D; Gardiman M; Gessi M; Ghimenton C; Giangaspero F; Lanza G; Marucci G; Novello M; Silini EM; Zunarelli E; Paccapelo A; Brandes AA
    Eur J Cancer; 2020 Sep; 137():10-17. PubMed ID: 32721633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
    Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
    J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation.
    Khurana R; Rath S; Singh HB; Rastogi M; Nanda SS; Chauhan A; Kaif M; Hussain N
    Asian Pac J Cancer Prev; 2020 Mar; 21(3):755-760. PubMed ID: 32212804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Collaborative overexpression of matrix metalloproteinase-1 and vascular endothelial growth factor-C predicts adverse prognosis in patients with gliomas.
    Xu Y; Zhong Z; Yuan J; Zhang Z; Wei Q; Song W; Chen H
    Cancer Epidemiol; 2013 Oct; 37(5):697-702. PubMed ID: 23870768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormal expression of
    Wang J; Liu Z; Zhang C; Wang H; Li A; Liu B; Lian X; Ren Z; Zhang W; Wang Y; Zhang B; Pang B; Gao Y
    PeerJ; 2021; 9():e10820. PubMed ID: 33614284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.
    Wang ZL; Li GZ; Wang QW; Bao ZS; Wang Z; Zhang CB; Jiang T
    Oncoimmunology; 2019; 8(2):e1541535. PubMed ID: 30713802
    [No Abstract]   [Full Text] [Related]  

  • 37. Protein disulphide isomerase can predict the clinical prognostic value and contribute to malignant progression in gliomas.
    Hu Q; Huang K; Tao C; Zhu X
    J Cell Mol Med; 2020 May; 24(10):5888-5900. PubMed ID: 32301283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrative Analysis of DNA Methylation and Gene Expression Identify a Three-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas.
    Zeng WJ; Yang YL; Liu ZZ; Wen ZP; Chen YH; Hu XL; Cheng Q; Xiao J; Zhao J; Chen XP
    Cell Physiol Biochem; 2018; 47(1):428-439. PubMed ID: 29794476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RAB34 was a progression- and prognosis-associated biomarker in gliomas.
    Wang HJ; Gao Y; Chen L; Li YL; Jiang CL
    Tumour Biol; 2015 Mar; 36(3):1573-8. PubMed ID: 25501506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
    Chen R; Cohen AL; Colman H
    Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.